Embrace Meeting - First Line Trials in post Menopausal Women

Speciality: Obstetrics and Gynecology


Speaker:

Dr. Chintan Shah - Moderator | Medical Oncologist HOC Vedanta

Dr. Murtaza Bohra - Case Presenter | Medical Oncologist National Cancer Institute

Dr. Ashish B. Agrawal - Expert Panelist | Medical Oncologist & Haematologist Kiran Multispecialty Hospital

Dr. Shivam Shingla - Expert Panelist | Medical Oncologist S L Raheja Hospital

Dr. Avinash Talele - Expert Panelist | Medical Oncologist Apollo Hospital

Description:

A warm welcome to all the medical professionals in this interesting session on Embrace Meeting - First Line Trials in post Menopausal Women 
The Embrace Meeting is a significant event that brings together experts to discuss the latest advancements in the treatment of postmenopausal women, focusing particularly on first-line clinical trials. This meeting provides a platform for sharing cutting-edge research, clinical experiences, and innovative strategies aimed at improving healthcare outcomes for this demographic.
 A key highlight of the Embrace Meeting is the discussion of first-line clinical trials specifically tailored for postmenopausal women. These trials explore the efficacy and safety of new therapeutic options in treating conditions prevalent in this group, such as osteoporosis, breast cancer, and cardiovascular disease. The aim is to identify optimal first-line treatments that offer the best balance of efficacy and tolerability.
These advancements represent potential game-changers in the management of health issues in postmenopausal women, offering hope for improved quality of life.
Therefore, get an overall knowledge of embrace meeting - first line trials in post menopuasal women
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In leukemia, allogeneic HCT is beneficial following primary induction failure.

2.

Team finds broken 'brake' on cancer mutation machine.

3.

Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer

4.

Prostate cancer screening program beneficial in top decile of polygenic risk score

5.

Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot